Clinuvel Pharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLVLF research report →
About the company
Clinuvel Pharmaceuticals Limited (CLVLF), an Australian biopharmaceutical firm established in Melbourne in 1987, specializes in the creation and global marketing of therapeutic solutions. Its primary focus is on patients suffering from genetic, metabolic, and severe, life-threatening conditions, with operations spanning Australia, Europe, the United States, Switzerland, and various international markets. The company's flagship product is SCENESSE, a systemic photoprotective medication.
- CEO
- Philippe Jacques Wolgen
- IPO
- 2009
- Employees
- 109
- HQ
- Melbourne, VIC, AU
Price Chart
- Market Cap
- $307.51M
- P/E
- 15.77
- P/S
- 5.37
- P/B
- 2.06
- EV/EBITDA
- 11.55
- Div Yield
- 0.49%
- Gross Margin
- 63.71%
- Op Margin
- 39.39%
- Net Margin
- 33.79%
- ROE
- 13.29%
- ROIC
- 11.07%
- Revenue
- $95.02M · 7.76%
- Net Income
- $36.17M · 1.50%
- EPS
- $0.72 · 0.00%
- Op Income
- $45.73M
- FCF YoY
- 29.61%
- 52W High
- $8.60
- 52W Low
- $6.10
- 50D MA
- $6.39
- 200D MA
- $7.54
- Beta
- 0.61
- Avg Volume
- 167
Get TickerSpark's AI analysis on CLVLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CLVLF coverage
Recent articles, reports, and earnings notes.
No research on CLVLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLVLF report →Similar companies
Peers in the same neighborhood.